Mise à jour des directives de la FMH: Chapitre 5 et Chapitre 6 – Agents hémostatiques et prophylaxie

Shannon Kelly currently manages and works as a senior research methodologist in the Heath Technology Assessment Unit of the Cardiovascular Research Methods Centre (CRMC) at the University of Ottawa Heart Institute where she focusses her work on advancing the science of evidence synthesis, research design and methodology. Her team conducts evidence syntheses to inform health care practice and policy. In this capacity, she has worked with a number of organizations nationally and internationally, including the Canadian Agency for Drugs and Technologies in Health (CADTH), the Public Health Agency of Canada, the World Health Organization and the Cochrane Collaboration.

Shannon is currently a PhD candidate in the Faculty of Medicine, School of Epidemiology and Public Health at the University of Ottawa and a trainee with the Cardiovascular Network of Canada (CANet) National Centre of Excellence. In her capacity with CANet, she sits on the Board of Directors. Shannon has been actively involved with post-market Drug Safety and Effectiveness Network (DSEN) since 2011 and has led numerous research projects for the Ontario Drug Policy Research Network, the Canadian Collaboration for Network Meta-analysis (CCNMA), the Methods and Application Group for Indirect Comparisons (DSEN- MAGIC) and the POst-market Drug Evaluation Team (PODET). In addition, Shannon leading a working group to develop nutrition-specific risk of bias tools (NUQUEST).